Press "Enter" to skip to content

Saliva Test Aids Spot Mild Cognitive Impairment And Alzheimer’s Disease

The researchers from the University of Alberta have found three biomarkers for identifying mild cognitive impairment or Alzheimer’s disease via saliva sample analysis. The research has promising results for application in a clinical setting.

The research squad merges the expertise in metabolomics including Liang Li from Department of Chemistry and Roger Dixon from Department of Psychology so as to understand the mental health conditions the people being affected with owing to the genetic, environmental, or lifestyle issues. The current study helps to focus on the approaching and surprising global impact of the neurodegenerative conditions or dementia. The two scientists used the saliva samples of the patients suffering from the Alzheimer’s disease, mild cognitive impairment along with a placebo patient. With the help of powerful mass spectrometer, the researchers were able to examine higher than 6,000 metabolites, which are the body’s metabolic processing compounds, so as to check for any changes in them. In the analysis process, the researchers found three specific metabolites that can help distinguish between the groups. Though the current study is just at its preliminary stage it seems to be a promising one. The larger sample testing can help can help make validation easier and also publicize the saliva test of the Alzheimer’s disease.

The saliva test’s easy method, non-invasive nature, and cost-effectiveness are going to make it a blockbuster in the clinical settings. The current test also helps identifying neurodegenerative diseases during their earlier stages and starts the necessary treatments at the early stage itself. To date, no ailment-changing interventions for Alzheimer’s disease have proved successful. The earliest signals of the disease are the effects the researchers are currently focusing so as to implement the disease prevention measures. The biomarker identification is an added advantage as the efficacy testing for the treatments can also be conducted. The specific treatments to be followed can also be tested depending on an individual’s physical activity to diet to pharmaceuticals. A new study led by scientists from Sanford Burnham Prebys Medical Discovery Institute helps to understand the brain-robbing illness origination and that an HIV enzyme has a role in lashing Alzheimer’s-related brain pathology by changing the APP gene.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *